Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 15/20 | 0.49 |
| ▸ | CTSS | P25774 | 9/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12635077 | 1.00 | CTSK (0.49) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL6977978 | 1.00 | CTSK (0.49) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL12635079 | 0.86 | CTSK (0.51) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL12635082 | 0.86 | CTSK (0.51) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL6971472 | 0.86 | CA1 (0.45) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL6968497 | 0.86 | CA1 (0.45) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL24046184 | 0.84 | CA1 (0.44) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL26129040 | 0.84 | CA1 (0.44) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL26129038 | 0.84 | CA1 (0.44) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL5450014 | 0.84 | CTSK (0.50) | CTSKCTSSCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9187415-B2 | Sulfonamides as HIV protease inhibitors | MERCK CANADA INC. (CA) | 2015-11-17 | — | — | US | disclosed |
| US-20140018326-A1 | SULFONAMIDES AS HIB PROTEASE INHIBITORS | MERCK CANADA INC. (CA) | 2014-01-16 | — | — | US | disclosed |
| WO-2011053821-A1 | MACROCYCLIC GHRELIN RECEPTOR ANTAGONISTS AND INVERSE AGONISTS AND METHODS OF USING THE SAME | TRANZYME PHARMA, INC. (US) | 2011-05-05 | — | — | WO | disclosed |
| US-20110105389-A1 | Macrocyclic Ghrelin Receptor Antagonists and Inverse Agonists and Methods of Using the Same | OCERA THERAPEUTICS, INC. | 2011-05-05 | — | — | US | disclosed |
| US-20110105389-A1 | Macrocyclic Ghrelin Receptor Antagonists and Inverse Agonists and Methods of Using the Same | OCERA THERAPEUTICS, INC. | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018326-A1 | SULFONAMIDES AS HIB PROTEASE INHIBITORS | PRSS1, PRSS3, PRSS2 | CTSK 767/4885CTSS 69/4885CA1 1243/4885 |
| US-20110105389-A1 | Macrocyclic Ghrelin Receptor Antagonists and Inverse Agonists and Methods of Using the Same | GHSR, GHRHR, GIPR | CTSK 4252/4885CTSS 2800/4885CA1 4864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.